Aristides Capital LLC Has $2.05 Million Holdings in BioNTech SE (NASDAQ:BNTX)

Aristides Capital LLC lifted its stake in shares of BioNTech SE (NASDAQ:BNTX) by 51.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 18,010 shares of the company’s stock after purchasing an additional 6,110 shares during the period. Aristides Capital LLC’s holdings in BioNTech were worth $2,052,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. abrdn plc lifted its holdings in BioNTech by 70.7% during the 4th quarter. abrdn plc now owns 385,668 shares of the company’s stock worth $43,947,000 after buying an additional 159,676 shares in the last quarter. Franklin Resources Inc. lifted its stake in shares of BioNTech by 3,942.1% during the fourth quarter. Franklin Resources Inc. now owns 136,786 shares of the company’s stock valued at $15,587,000 after acquiring an additional 133,402 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in BioNTech by 123.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 134,036 shares of the company’s stock valued at $15,919,000 after acquiring an additional 74,119 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in BioNTech in the fourth quarter worth about $7,128,000. Finally, Flossbach Von Storch SE raised its holdings in BioNTech by 1.1% during the 4th quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company’s stock worth $502,160,000 after purchasing an additional 47,236 shares during the last quarter. 15.52% of the stock is owned by institutional investors.

BioNTech Stock Performance

Shares of BNTX stock opened at $88.05 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The company’s 50 day moving average price is $108.81 and its two-hundred day moving average price is $112.80. The company has a market capitalization of $21.13 billion, a P/E ratio of -41.93 and a beta of 1.07.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s quarterly revenue was down 19.5% on a year-over-year basis. During the same period last year, the business posted $1.90 earnings per share. On average, analysts expect that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on BNTX shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $171.44 target price on shares of BioNTech in a research note on Tuesday, March 11th. Wells Fargo & Company began coverage on shares of BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 target price for the company. BMO Capital Markets increased their price target on BioNTech from $130.00 to $143.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Morgan Stanley reduced their price target on BioNTech from $145.00 to $139.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 11th. Finally, Truist Financial began coverage on BioNTech in a report on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $143.44.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.